Related Experiment Video
Updated: Jan 22, 2026

In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol
Published on: December 30, 2016
Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan
Takuya Imatoh1, Kimie Sai1, Mayu Takeyama2
1Division of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki, Japan.
Insights
Regulatory action in Japan significantly increased calcium supplementation with denosumab, preventing a rise in hypocalcaemia. This highlights the effectiveness of safety communications in clinical practice.
Area of Science:
- Pharmacovigilance and Drug Safety
- Health Services Research
- Clinical Pharmacology
Background:
- Denosumab, introduced in April 2012, was associated with serious hypocalcaemia, including fatalities, prompting a safety communication ('Blue letter') in Japan.
- Understanding the real-world impact of such regulatory actions on clinical practice and patient safety is crucial.
Purpose of the Study:
- To evaluate the impact of a regulatory safety communication on denosumab-induced hypocalcaemia in Japan.
- To assess changes in calcium supplementation and monitoring practices following the safety warning.
Main Methods:
- Utilized two electronic medical information databases (MIDs) covering patients prescribed denosumab or zoledronic acid (April 2012-September 2014).
- Assessed four key indicators: calcium supplementation, serum calcium testing rates and frequency, and hypocalcaemia prevalence, aggregated quarterly.
- Employed difference-in-difference (DID) analysis to evaluate the regulatory action's impact.
Main Results:
- The proportion of patients receiving calcium supplementation at initial denosumab treatment increased consistently across both datasets.
- Data set two showed an increase in the average number of serum calcium tests performed.
- Difference-in-difference analysis revealed significant positive influences of the regulatory action on the combination use of denosumab with calcium and vitamin D supplements in both datasets.
Conclusions:
- The regulatory action significantly influenced the co-prescription of denosumab with calcium and/or vitamin D supplements.
- The absence of a notable increase in denosumab-induced hypocalcaemia suggests the regulatory action was effective in the studied clinical settings.
- Regulatory safety communications play a vital role in enhancing drug safety in clinical practice.
What Is Known And Objective:
Since its introduction in April 2012, denosumab has been administered to approximately 7,300 patients as of August 2012, and 32 cases of serious hypocalcaemia after denosumab administration, including two deaths, have been reported in Japan. A Dear Healthcare Professional Letter of Rapid Safety Communication ('Blue letter') was released to warn about the risks of hypocalcaemia associated with denosumab. The goal of this study therefore was to measure the impact of regulatory action on denosumab-induced hypocalcaemia in Japan by using an electronic medical information database (MID).
Methods:
We used two different aggregated data sets based on MIDs (data sets one and two). The patients studied were those who were newly prescribed denosumab or zoledronic acid between April 2012 and September 2014. We assessed four indicators: (a) the proportion of patients with calcium supplementation at the initial denosumab treatment, (b) the proportion of patients who underwent a serum calcium test, (c) the average number of serum calcium tests performed and (d) the prevalence of hypocalcaemia. All indices were aggregated by every 3 months. To evaluate the impact of regulatory action, we used difference in difference (DID) analysis.
Results And Discussion:
The proportion of patients with calcium supplementation at the initial denosumab treatment increased year by year in both data sets. The average number of serum calcium tests increased year by year in data set two. There was a significant difference in the prevalence of hypocalcaemia in data set two. This suggests that the estimate of impact of the regulatory action may vary according to the database. In DID analysis, however, significant influences of the regulatory action on combination use with a calcium supplement were detected in both data sets.
What Is New And Conclusion:
There was a significant influence on combination use of denosumab with vitamin D and/or calcium supplement in both data sets. That there was no apparent increase in the prevalence of denosumab-induced hypocalcaemia, suggests that the regulatory action had an impact in the clinical setting studied. Such regulatory actions may play an important role in the promotion of drug safety.
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Cis-regulatory Sequences
Cis-regulatory Sequences
Fixed Action Patterns
Impact of Groups on Groups
Global Regulatory Systems

